Journal article
Myostatin inhibition therapy for insulin-deficient type 1 diabetes
Abstract
While Type 1 Diabetes Mellitus (T1DM) is characterized by hypoinsulinemia and hyperglycemia, persons with T1DM also develop insulin resistance. Recent studies have demonstrated that insulin resistance in T1DM is a primary mediator of the micro and macrovascular complications that invariably develop in this chronic disease. Myostatin acts to attenuate muscle growth and has been demonstrated to be elevated in streptozotocin-induced diabetic …
Authors
Coleman SK; Rebalka IA; D’Souza DM; Deodhare N; Desjardins EM; Hawke TJ
Journal
Scientific Reports, Vol. 6, No. 1,
Publisher
Springer Nature
DOI
10.1038/srep32495
ISSN
2045-2322
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsCrosses, GeneticDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Founder EffectGene Expression RegulationGenetic TherapyGlucoseGlucose Transporter Type 1Glucose Transporter Type 4HyperglycemiaInsulinInsulin ResistanceMiceMice, Inbred C57BLMice, KnockoutMuscle WeaknessMuscle, SkeletalMyostatinRNA, MessengerSignal Transduction